<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="54888">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02391584</url>
  </required_header>
  <id_info>
    <org_study_id>2909-001</org_study_id>
    <nct_id>NCT02391584</nct_id>
  </id_info>
  <brief_title>XprESS Eustachian Tube Dilation Study</brief_title>
  <official_title>XprESS Eustachian Tube Dilation Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Entellus Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Entellus Medical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to assess the safety and efficacy of the XprESS device for transnasal Eustachian tube
      dilation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, multicenter, randomized controlled trial comparing balloon dilation of the
      Eustachian tube to continued medical management for treatment of persistent Eustachian tube
      dysfunction.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall change in ETDQ-7 scores from baseline</measure>
    <time_frame>6 weeks post procedure (treatment arm) or randomization (control arm)</time_frame>
    <description>Comparison of mean change in overall ETDQ-7 scores from baseline to 6 weeks between randomized arms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complication rate</measure>
    <time_frame>Through 6 months post-procedure</time_frame>
    <description>Number of subjects who experience serious device- or procedure-related adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Technical success rate</measure>
    <time_frame>Immediately after procedure</time_frame>
    <description>Percent of successful ET dilations per attempted ET dilations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Revision rate</measure>
    <time_frame>12 months</time_frame>
    <description>Percent of participants undergoing repeat balloon dilation procedure on an ET that was initially treated with an XprESS device</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in overall ETDQ-7 score</measure>
    <time_frame>12 months</time_frame>
    <description>Mean change from baseline to 12 months in the overall ETDQ-7 score at all follow-up periods</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Eustachian Tube Dysfunction</condition>
  <arm_group>
    <arm_group_label>XprESS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Balloon dilation of the Eustachian tube</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Continued medical management</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>XprESS</intervention_name>
    <description>Balloon dilation of the Eustachian tube</description>
    <arm_group_label>XprESS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Continued current medical management</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  â‰¥18 years old

          -  Have been diagnosed with symptoms of chronic Eustachian tube dysfunction for no less
             than 12 months prior to enrollment

          -  Have record of failed medical management for Eustachian tube dysfunction

        Exclusion Criteria:

          -  Have evidence of internal carotid artery dehiscence

          -  Be pregnant at the time of enrollment

          -  Be currently participating in other drug or device studies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Colorado Sinus Institue</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 7, 2016</lastchanged_date>
  <firstreceived_date>March 9, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
